Trethera Announces Clinical Progress for TRE-515 Cancer and Autoimmune Drug

Trethera Corporation, a clinical stage biopharmaceutical company developing first-in-class therapies for cancer and autoimmune diseases, announced on February 12, 2026 that it will present at the 16th Annual Biocom Global Partnering and Investor Conference following the successful completion of its Phase 1 solid tumor dose escalation trial and FDA Fast Track designation for prostate cancer.

Biocom selected Trethera as a featured presenter following a strong close to 2025, highlighted by the successful completion of its Phase 1 solid tumor dose escalation trial and FDA Fast Track designation for prostate cancer. A favorable safety profile has been established with evidence of target engagement and early clinical activity. These results position Trethera's lead drug, TRE-515, to advance as a multi-indication program across both oncology and autoimmune diseases.

The FDA has designated TRE-515 a Fast Track drug for prostate cancer and an Orphan Drug for two autoimmune neurologic diseases. Ongoing preclinical, clinical and translational work is expected to inform upcoming indication expansion and next stage clinical trials.

The Chairman and CEO stated that the potential for TRE-515 to treat a broad spectrum of diseases creates a pipeline-in-a-product approach that reduces overall development risk. Completing oncology dose escalation was described as a pivotal milestone that positions Trethera to advance parallel clinical development efforts and efficiently expand patient trials. The conference comes at an ideal time as Trethera transitions from dose finding to indication expansion and the next phase of clinical growth.

The presentation will take place on Tuesday, February 24, 2026 from 1:30PM to 2:00 PM at The Lodge at Torrey Pines in La Jolla, California. The presentation is titled "Treatment of Cancer and Autoimmune Disease with a Clinical Stage, Orphan Drug Designated, First-in-Class Deoxycytidine Kinase Inhibitor" and will be part of Track B, Novel Therapeutics. The presenter will be the company's Chairman and CEO.

Biocom convenes more than 500 institutional investors and senior executives from leading pharmaceutical, biotechnology, and research organizations across more than 20 countries. The conference features a highly curated program of podium presentations, panel discussions with industry thought leaders, and targeted partnering meetings, making it a premier forum for strategic dialogue and deal formation in the global life sciences ecosystem.

Trethera is a clinical stage, privately held, biopharmaceutical company founded by prominent UCLA scientists. TRE-515 is an orally administered capsule and a first-in-class clinical stage drug that inhibits deoxycytidine kinase (dCK), the rate-limiting enzyme in the nucleoside salvage pathway, one of two biosynthetic pathways that generate DNA precursors. It is believed that some forms of cancer may be preferentially dependent on the salvage pathway to support tumor growth, and certain autoimmune diseases might also respond to TRE-515 treatment. TRE-515 blocks the salvage pathway, which becomes upregulated during cancer growth and autoimmune disease. Trethera is developing TRE-515 for use as a monotherapy or in combination to precisely target a metabolic vulnerability of cancer or autoimmune diseases that will transform outcomes for patients.